Armenta is a brand that aims to tackle the pressing issue of Bovine Mastitis, a disease that significantly affects dairy farming. With losses reaching billions of dollars annually, Armenta has developed innovative non-invasive and antibiotics-free therapies based on acoustic pulse technology (APT). Drawing on over 20 years of experience in human healthcare, where APT has been successfully used to treat inflammatory diseases, Armenta's team of experts in acoustic pulse treatment, engineering, mastitis research, and ex-dairy farming have developed optimal solutions for bovine mastitis.

Armenta's revolutionary APT solution helps to ensure healthier cows, more profitable farms, and better milk. By reducing the need for antibiotics, APT strengthens cows' immune systems, making them less susceptible to repeated infections and ultimately increasing milk yield and quality. This technology also addresses evolving consumer concerns about health, the environment, and animal welfare, meeting the demand for high-quality and safe dairy products.

Moreover, Armenta's non-invasive, repeatable, and safe approach bridges the gap in antimicrobial resistance (AMR) by effectively treating mastitis without the use of antibiotics. The company actively supports the One Health approach, recognizing the interconnectedness between the health of people, animals, and the environment. With the expertise and dedication of its management team, including Chairman & CEO Gil Hakim, Founder & CTO Eddie Papirov, CSO Prof.

Gabriel Leitner, COO Ilanit Frank Hakim, and VPs Dani Gilad and Dan Baratz, Armenta is leading the way in developing novel treatments for dairy cattle diseases